A Current and Future Perspective on Adjuvant and Neoadjuvant Recirculating Chemohyperthermia as a Treatment for Intermediate-High Risk NMIBC| Chapter 5 | Current Overview on Disease and Health Research Vol. 2

 

Nearly 75% of bladder cancer diagnoses are for non-muscle invasive bladder cancer (NMIBC), and more than half of these cases relapse after transurethral excision of the bladder tumour. Traditional methods for preventing recurrences include immunotherapy with bacillus Calmette-Guérin (BCG) and adjuvant intravenous chemotherapy with mitomycin C (MMC). Unfortunately, after receiving these therapies, a lot of people relapse, and a lot of them will need surgery. After one to three years of BCG maintenance, there was a risk of over 19 percent for T1G3 tumours to progress. Adjuvant intravesical therapy is being studied using a variety of cutting-edge therapeutic modalities. One of the most recent therapies for intermediate and high-risk NMIBC is chemohyperthermia (CHT), which combines intravesical chemotherapy and hyperthermia. This article's goal is to evaluate recirculating chemohyperthermia's mechanism of action, current status and indications, outcomes, and potential in the treatment of intermediate-to-high risk NMIBC.

Author(s) Details:

Juan Leon-Mata,
Urology Service, Comarcal Hospital of Monforte, Rua Corredoira, S/N 27.400 Monforte de Lemos (Lugo), Spain.

Daniel Sousa-Gonzalez,
Family and Community Medicine, Universitary Hospital of Lugo, Rúa Dr. Ulises Romero, 1, 27003, Lugo, Spain.

Maria Alvarez-Casal,
Family and Community Medicine, Universitary Hospital of Lugo, Rúa Dr. Ulises Romero, 1, 27003, Lugo, Spain.

Javier Flores-Carbajal,
Urology Service, Comarcal Hospital of Monforte, Rua Corredoira, S/N 27.400 Monforte de Lemos (Lugo), Spain.

Alejandro Sousa-Escandón,
Urology Service, Comarcal Hospital of Monforte, Rua Corredoira, S/N 27.400 Monforte de Lemos (Lugo), Spain.

Please see the link here: https://stm.bookpi.org/CODHR-V2/article/view/7745